In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.

[1]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[2]  Akshay S. Desai,et al.  Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial , 2018, JAMA cardiology.

[3]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[4]  Akshay S. Desai,et al.  Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial , 2018, JAMA cardiology.

[5]  Emily C. O'Brien,et al.  Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). , 2017, JACC. Heart failure.

[6]  Wing W. Chan,et al.  Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.

[7]  S. Solomon,et al.  Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. , 2016, JAMA cardiology.

[8]  Akshay S. Desai,et al.  Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. , 2016, Journal of the American College of Cardiology.

[9]  S. Solomon,et al.  Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. , 2015, The New England journal of medicine.

[10]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.